Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo

• Published in: mSystems 2023-10, Vol.8 (5), p.e0067023-e0067023
• Main Authors: Wang, Sihan, Zhang, Tian-Hao, Hu, Menglong, Tang, Kejun, Sheng, Li, Hong, Mengying, Chen, Dongdong, Chen, Liubo, Shi, Yuan, Feng, Jun, Qian, Jing, Sun, Lifeng, Ding, Kefeng, Sun, Ren, Du, Yushen
• Format: Article
• Language: English
• Subjects: deep mutational scanning; drug-resistant mutations; influenza; neuraminidase
• ISSN: 2379-5077; 2379-5077
• DOI: 10.1128/msystems.00670-23

NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA's mutational effect and drug resistance profiles is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs.